Pulmonary pseudoaneurysm in the setting of concurrent COVID-19 and pulmonary mucormycosis: A rare case report.
Hussein HamdarAli Alakbar NahleRida JaberHadi SalameAmjad SikariaYounes SouleimanPublished in: Clinical case reports (2023)
Pulmonary mucormycosis (PM) is a highly lethal invasive infection. It is a rare complication of COVID-19 and is associated with a high mortality rate. Pulmonary pseudoaneurysm (PAP) is a severe manifestation of this condition, often resulting in death. Management involves endovascular therapy followed by surgery and appropriate antifungal treatment.
Keyphrases
- pulmonary hypertension
- coronavirus disease
- sars cov
- case report
- minimally invasive
- particulate matter
- cardiovascular disease
- heavy metals
- risk factors
- early onset
- candida albicans
- coronary artery bypass
- bone marrow
- respiratory syndrome coronavirus
- mesenchymal stem cells
- coronary artery disease
- polycyclic aromatic hydrocarbons
- combination therapy
- replacement therapy
- smoking cessation